Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3343-3351

  Oudard, Stéphane ^a   Banu, Eugeniu ^a   Beuzeboc, Philippe ^a   Voog, Eric ^a   Dourthe, Louis Marie ^a   Hardy Bessard, Anne Claire ^a   Linassier, Claude ^a   Scotté, Florian ^a   Banu, Adela ^a   Coscas, Yvan ^a   Guinet, François ^a   Poupon, Marie France ^a   Andrieu, Jean Marie ^a  

^a CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; WARFARIN; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CANCER INVASION; CANCER STAGING; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK FACTOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOXANTRONE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 20644448225     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.187     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
2. Petrylak DP: Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 20:31-35, 2002
3. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
4. Tannock IF, Osoba D, Stockier MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
5. Ernst DS, Tannock IF, Winquist EW, et al: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335-3342, 2003
6. Dahllof B, Billstrom A, Cabral F, et al: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581, 1993
7. Kreis W, Budman DR, Calabro A: Unique synergism or antagonism of combinations of chemotherapy and hormonal agents in human prostate cancer cell lines. Br J Urol 79:196-202, 1997
8. Kreis W, Budman DR, Fetten J, et al: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38, 1999
9. Petrylak DP, Macarthur RB, O'Connor J, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967, 1999
10. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457-1465, 2002
11. Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780: Cancer and Leukemia Group B. J Clin Oncol 19:2509-2516, 2001
12. Oudard S, Legrier ME, Boye K, et al: Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 169:1729-1734, 2003
13. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
14. Boureau F, Luu M, Doubrere JF: Comparative study of the validity of four French McGill Pain Questionnaire (MPQ) versions. Pain 50:59-65, 1992
15. Bland JM, Altman DG: Multiple significance tests: The Bonferroni method. BMJ 310: 170, 1995
16. Small EJ, Vogelzang NJ: Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 15:382-388, 1997
17. Sartor O, Weinberger M, Moore A, et al: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52:252-256, 1998
18. Tannock IF, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
19. Storlie JA, Buckner JC, Wiseman GA, et al: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76:96-100, 1995
20. Weitzman AL, Shelton G, Zuech N, et al: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163:834-837, 2000
21. Akakura K, Suzuki H, Ueda T, et al: Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6. Prostate 56:106-109, 2003
22. Berry WR, Laszlo J, Cox E, et al: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763-775, 1979
23. Emrich LJ, Priore RL, Murphy GP, et al: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45:5173-5179, 1985
24. Kelly WK, Scher HI, Mazumdar M, et al: Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 11:607-615, 1993
25. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953, 1995
26. Petrylak DP, Scher HI, Li Z, et al: Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70:2870-2878, 1992